BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:43 PM
 | 
Aug 11, 2009
 |  BC Extra  |  Clinical News

Genmab reports first-line CLL data for Arzerra

Genmab A/S (CSE:GEN) said top-line data showed 500 and 1,000 mg Arzerra ofatumumab in combination with fludarabine and cyclophosphamide led to complete remission rates of 32%...

Read the full 116 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >